Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
about
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceEvolving concepts in cancer therapy through targeting sphingolipid metabolismApolipoprotein A-I: insights from redox proteomics for its role in neurodegenerationA unique carrier for delivery of therapeutic compounds beyond the blood-brain barrierPathway analysis for drug repositioning based on public database miningLiposome-Cross-Linked Hybrid Hydrogels for Glutathione-Triggered Delivery of Multiple Cargo MoleculesDoxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking.Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.Selection and characterization of small molecules that bind the HIV-1 frameshift site RNA.Metabolic interrogation as a tool to optimize chemotherapeutic regimens.Synthesis and anti-breast cancer evaluation of novel N-(guanidinyl)benzenesulfonamidesEnhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells.Oscillatory dynamics in a model of vascular tumour growth--implications for chemotherapyDevelopment and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells.Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cellsMultiplex assay for condition-dependent changes in protein-protein interactions.Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicinVitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response.Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model?Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistanceMutS homologue hMSH5: recombinational DSB repair and non-synonymous polymorphic variantsSpecific targeting of A54 homing peptide-functionalized dextran-g-poly(lactic-co-glycolic acid) micelles to tumor cells.A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activityChemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel.Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fearsEpithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.Nuclear mapping of nanodrug delivery systems in dynamic cellular environmentsDoxorubicin Changes Bax /Bcl-xL Ratio, Caspase-8 and 9 in Breast Cancer Cells.Effects of fermented Cordyceps sinensis on oxidative stress in doxorubicin treated rats.p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.Understanding drugs in breast cancer through drug sensitivity screeningAssociation of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer PatientsIntraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors.Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugsDifferent Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or DocetaxelTranscriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases.
P2860
Q24645668-3B840343-75B8-4A78-B412-58E0BACF3F57Q26863646-CE8E070C-E262-41BB-8D7A-8FC23643A40AQ27026686-59595DAC-6972-44A9-B535-7F3213C14CDFQ28472987-6314628B-19CA-43D6-A8CE-F61DF40D047DQ28657698-76657308-39B5-4C92-8508-A617B7A603F5Q28829477-61A168EF-7825-4F96-A068-F96A2574C0EBQ30472420-F23572F1-0669-4A31-AEB7-9B57EE386543Q33396676-5994FE10-E73C-4741-8D36-8D2FDE6542FEQ33492916-B34FF96C-A920-49AF-8204-A721672F0353Q33566853-E40A053E-E7C3-45EF-A19B-A48CAE2F2F03Q33580445-78490594-B0F7-4070-A18C-D9E573FCF9BEQ33632575-58B78688-B78E-4C2D-8B28-5E7EE4FB184DQ33755827-3AB75AEE-1386-442A-925B-E69E22464DC9Q33878725-8C493E4D-1833-4659-9D1F-A996540CFB3EQ34087482-545B7547-400E-473D-80AB-761F4C0E2FDDQ34227784-29ADA653-9284-41DE-9A1F-A4253A0E6B9BQ34276880-18DE2A4D-DE78-455C-9291-5E8882197ED6Q34283227-DCB0B5A9-493B-4EF9-B6F4-B2B37563A9BDQ34292480-ADC05877-FA3E-4A20-A814-22FC2A51DD04Q34321360-C5CBE19E-14DC-4C5F-AC02-4292F0EE23CAQ34708283-FDC4669F-F9B3-4746-9061-88D570E88692Q34714270-169A83F2-2CBE-46BE-954B-9E36B45386AFQ34984353-AE6BBA38-8EBC-49E7-A2E0-D5C16A67BF4FQ35001775-A28F8562-D8AF-4BC4-B8B1-CC5592C45D61Q35132272-8B944DF6-9D38-46CD-A5FF-B5333D5DD7C9Q35560987-D82AEEF0-4591-43E8-A332-1A7BC1D0205EQ35575502-345725D6-6002-4E6A-BB09-C5CAB424CB82Q35774310-C2D2639D-BB1C-4BD4-ACCC-65F53931DC9CQ35960157-DD95CFFC-F1AB-435B-9066-0D60DCC71B91Q36060654-0C09C3A4-F1A6-48BE-AF98-5A1A54FCE14DQ36196067-FCB4C2BD-4D61-4C99-A1FF-9BDC1DD7A00EQ36209961-E1A3F9CF-8890-4A8A-876A-9E22AE43C496Q36216301-0FD81AB2-022A-4652-A445-EE9ADD1BEF4CQ36234079-46E94D31-20D5-4206-94C1-5782EB9D6812Q36236476-7AEF9CBF-0C04-4E30-BA65-FC9201F9770CQ36338289-AF295049-3F97-4A7B-8B36-E93E2A76E8F1Q36438413-6CBFAE47-640D-4299-A3C1-128F85DC5863Q36502354-E75624C6-4658-4D7D-95AD-A1A71319FACCQ36652542-7C27F268-88BF-47BF-B6A6-7DEFF007A5ACQ36670771-0DDA9C6D-A8A9-40D8-980B-601A6993EEC9
P2860
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@ast
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@en
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@nl
type
label
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@ast
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@en
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@nl
prefLabel
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@ast
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@en
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@nl
P2093
P1476
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
@en
P2093
Fornari FA
Gewirtz DA
Randolph JK
Yalowich JC
P304
P577
1994-04-01T00:00:00Z